| Literature DB >> 34976807 |
Hang Lin1,2, Ge'ao Liang3, Huiping Chai4, Yongde Liao5, Chunfang Zhang1,6,7, Yuanda Cheng1,6,7.
Abstract
OBJECTIVE: The optimal technique for the thoracoscopic construction of an intrathoracic esophagogastric anastomosis continues to be a subject of controversy. The aim of this study was to compare the perioperative outcomes of circular-stapled anastomosis using a transorally inserted anvil (Orvil™) with those of circular-stapled anastomosis using a transthoracically placed anvil (non-Orvil™) in totally minimally invasive Ivor Lewis esophagectomy (Ivor Lewis TMIE).Entities:
Keywords: anastomotic leakage; anastomotic technique; esophageal cancer; minimally invasive Ivor Lewis esophagectomy; thoracoscopic intrathoracic esophagogastric anastomosis
Year: 2021 PMID: 34976807 PMCID: PMC8716395 DOI: 10.3389/fonc.2021.759599
Source DB: PubMed Journal: Front Oncol ISSN: 2234-943X Impact factor: 6.244
Figure 1Flowchart for propensity score matching analysis.
Figure 2Non-OrvilTM CS anastomosis using a transthoracically placed anvil (A) versus Orvil TM CS anastomosis using a transorally inserted anvil (B, C) during Ivor Lewis TMIE. d was defined as the distance between the location of the small opening and the staple line of the esophageal stump. r was defined as the radius of the anvil.
Patient baseline characteristics .
| Characteristics | Unmatched patients | Matched patients | ||||
|---|---|---|---|---|---|---|
| Orvil™ anastomosis (n=112) | Non-Orvil™ anastomosis (n=75) |
| Orvil™ anastomosis (n=65) | Non-Orvil™ anastomosis (n=65) |
| |
| Age, years | 64.0 (58.0 - 69.8) | 62.0 (54.0 - 66.0) | 0.008 | 62.0 (54.0 - 68.0) | 62.0 (54.5 - 67.0) | 0.950 |
| Sex, n (%) | 0.055 | 0.784 | ||||
| Male | 88 (78.6) | 67 (89.3) | 58 (89.2) | 57 (87.7) | ||
| Body mass index, kg/m2 | 22.0 ± 3.2 | 23.0 ± 3.3 | 0.045 | 22.5 ± 3.0 | 22.6 ± 2.6 | 0.854 |
| Cigarette smoking, n (%) | 0.083 | 0.276 | ||||
| Yes | 62 (55.4) | 51 (68.0) | 38 (58.5) | 44 (67.7) | ||
| Alcohol consumption, n (%) | 0.456 | 0.725 | ||||
| Yes | 55 (49.1) | 41 (54.7) | 34(52.3) | 36 (55.4) | ||
| Comorbidities, n (%) | ||||||
| Hypertension | 24 (21.4) | 12 (16.0) | 0.356 | 12 (18.5) | 12 (18.5) | 1.000 |
| Diabetes | 5 (4.5) | 1 (1.3) | 0.404 | 1 (1.5) | 1 (1.5) | 1.000 |
| Cerebrovascular disease | 7 (6.3) | 7 (9.3) | 0.432 | 6 (9.2) | 7 (10.8) | 0.770 |
| Peptic ulcer | 7 (6.3) | 5 (6.7) | 1.000 | 6 (9.2) | 5 (7.7) | 0.753 |
| Preoperative hemoglobin level, mg/dL | 134.0 (121.3 - 142.0) | 135.0 (126.0 - 145.0) | 0.279 | 137.0 (122.0 - 147.0) | 134.0 (125.0 - 143.5) | 0.670 |
| Preoperative albumin level, mg/dL | 41.5 ± 5.1 | 38. 8 ± 5.2 | <0.001 | 40.2 ± 5.0 | 39.0 ± 5.5 | 0.190 |
| Tumor location, n (%) | 0.036 | 0.441 | ||||
| Middle thoracic part | 45 (40.2) | 19 (25.3) | 21 (32.3) | 17 (26.2) | ||
| Lower thoracic part | 67 (59.8) | 56 (74.7) | 44 (67.7) | 48 (73.8) | ||
| Tumor size, cm | 3.5 (2.5 - 4.5) | 4.0 (3.0 - 5.0) | <0.001 | 3.7 (2.9 - 5.0) | 4.0 (3.0 - 5.0) | 0.071 |
| Tumor histology, n (%) | 0.927 | 0.910 | ||||
| Squamous cell carcinomas | 101 (90.2) | 69 (92.0) | 57 (87.7) | 59 (90.8) | ||
| Adenocarcinoma | 6 (5.4) | 3 (4.0) | 5 (7.7) | 3 (4.6) | ||
| Other | 5 (4.5) | 3 (4.0) | 3 (4.6) | 3 (4.6) | ||
| Tumor stage, n (%) | 0.526 | 0.464 | ||||
| 0 | 2 (1.8) | 2 (2.7) | 2 (3.1) | 2 (3.1) | ||
| I | 17 (15.2) | 12 (16.0) | 7 (10.8) | 9 (13.8) | ||
| II | 61 (54.5) | 33 (44.0) | 37 (56.9) | 27 (41.5) | ||
| III | 27 (24.1) | 26 (34.7) | 15 (23.1) | 25 (38.5) | ||
| IV | 5 (4.5) | 2 (2.7) | 4 (6.2) | 2 (3.1) | ||
Values are mean ± SD, median (IQR), or n (%).
Clinical outcomes, matched analysis (1:1).
| Variables | Orvil™ anastomosis (n=65) | Non-Orvil™ anastomosis (n=65) |
|
|---|---|---|---|
| Operation time, minutes | 258.8 ± 75.2 | 287.6 ± 75.5 | 0.031 |
| Intraoperative hemorrhage, ml | 150.0 (50.0 - 300.0) | 250.0 (200.0 - 500.0) | <0.001 |
| Intraoperative transfusions, n (%) | 5 (7.7) | 16 (24.6) | 0.009 |
| Length of chest tube duration, days | 9.0 (7.0 - 11.5) | 5.0 (4.0 - 6.5) | <0.001 |
| Length of nasogastric tube duration, days | 9.0 (7.0 - 13.0) | 10.0 (9.0 - 12.0) | 0.405 |
| Postoperative oral feeding time, days | 8.0 (7.0 - 11.0) | 9.0 (8.0 - 11.0) | 0.010 |
| Postoperative major complications, n (%) | 12 (18.5) | 17 (26.2) | 0.292 |
| Length of postoperative hospital stay, days | 11.0 (9.0 - 16.0) | 14.0 (11.5 - 16.0) | 0.001 |
| Total hospitalization costs, RMB | 76,103.8 (64,518.3 - 105,933.7) | 98,651.3 (92,804.4 - 110,773.9) | <0.001 |
Values are median (IQR), or n (%).
Postoperative major complications, matched analysis (1:1).
| Complications | Orvil™ anastomosis (n = 65) | Non-Orvil™ anastomosis (n = 65) |
|
|---|---|---|---|
| Wound infection, n (%) | 6 (9.2) | 2 (3.1) | 0.273 |
| Anastomotic stricture, n (%) | 1 (1.5) | 5 (7.7) | 0.208 |
| Anastomotic leakage, n (%) | 1 (1.5) | 8 (12.3) | 0.033 |
| Gastric emptying dysfunction, n (%) | 2 (3.1) | 0 (0.0) | 0.496 |
| Arrhythmia, n (%) | 0 (0.0) | 2 (3.1) | 0.496 |
| Pulmonary infection, n (%) | 4 (6.2) | 6 (9.2) | 0.510 |
| Chylothorax, n (%) | 1 (1.5) | 1 (1.5) | 1.000 |
Values are n (%).
Logistic regression analysis of variables comparing the anastomotic leakage and nonanastomotic leakage patients.
| Variables | n | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|---|
| OR (95% CI) |
| OR (95% CI) |
| ||
| Sex | 0.546 | ||||
| Male | 155 | 1 | |||
| Female | 32 | 0.523 (0.064 - 4.282) | |||
| Cigarette smoking | 0.084 | ||||
| No | 74 | 1 | |||
| Yes | 113 | 6.317 (0.783 - 50.950) | |||
| Alcohol consumption | 0.237 | ||||
| No | 91 | 1 | |||
| Yes | 96 | 2.307 (0.578 - 9.209) | |||
| Hypertension | 0.951 | ||||
| No | 151 | 1 | |||
| Yes | 36 | 1.051 (0.214 - 5.177) | |||
| Cerebrovascular disease | 0.757 | ||||
| No | 173 | 1 | |||
| Yes | 14 | 1.402 (0.165 - 11.935) | |||
| Peptic ulcer | 0.638 | ||||
| No | 175 | 1 | |||
| Yes | 12 | 1.677 (0.194 - 14.456) | |||
| Tumor location | 0.773 | ||||
| Middle thoracic part | 64 | 1 | |||
| Lower thoracic part | 123 | 1.227 (0.306 - 4.914) | |||
| Anastomotic techniques | 0.019 | 0.027 | |||
| Non-Orvil™ anastomosis | 75 | 1 | 1 | ||
| Orvil™ anastomosis | 112 | 0.152 (0.031 - 0.739) | 0.114(0.016 - 0.781) | ||
| Pulmonary infection | <0.001 | <0.001 | |||
| No | 176 | 1 | 1 | ||
| Yes | 11 | 51.600 (10.992 - 242.229) | 65.129(10.717 - 395.781) | ||
OR, odds ratio; CI, confidence interval.